Loss of GABARAPL1 confers ferroptosis resistance to cancer stem-like cells in hepatocellular carcinoma

被引:18
|
作者
Du, Xiaojing [1 ,2 ]
Qi, Zhuoran
Xu, Jinzhi [3 ]
Guo, Mengzhou [3 ]
Zhang, Xingxing [2 ,3 ,4 ]
Yu, Zhijie [2 ,5 ]
Cao, Xin [6 ]
Xia, Jinglin [1 ,2 ,3 ]
机构
[1] Fudan Univ, Minhang Hosp, Dept Gastroenterol, Shanghai, Peoples R China
[2] Wenzhou Med Univ, Affiliated Hosp 1, Key Lab Diag & Treatment Severe Hepatopancreat Di, Wenzhou 325000, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Shanghai, Peoples R China
[4] Anhui Univ Sci & Technol, Affiliated Fengxian Hosp, Shanghai Fengxian Dist Cent Hosp, Dept Gastroenterol, Shanghai, Peoples R China
[5] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou Key Lab Hematol, Wenzhou, Peoples R China
[6] Fudan Univ, Inst Clin Sci, Zhongshan Hosp, Shanghai 200032, Peoples R China
基金
上海市自然科学基金; 中国国家自然科学基金;
关键词
cancer stem-like cell; ferroptosis; GABARAPL1; hepatocellular carcinoma; sorafenib;
D O I
10.1002/1878-0261.13305
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer stem-like cells (CSLC) are considered a major contributor to the development and progression of hepatocellular carcinoma (HCC). Previous studies indicated that CSLC are characterized by resistance to ferroptosis, a type of lipid peroxidation-dependent cell death. Here, we identified a set of ferroptosis-related stemness genes (FRSG) and found that these genes may be involved in immune infiltration in HCC. A four-FRSG (CDKN2A, GABARAPL1, HRAS, RPL8) risk model with prognostic prediction was constructed by a Cox analysis in HCC. Among these four genes, GABARAPL1 was downregulated in HCC tumor-repopulating cells (TRC; a type of CSLC). Its downregulation decreased the sensitivity of HCC TRC to erastin- or sorafenib-triggered ferroptosis. Together, we uncovered a molecular mechanism via which CSLC could achieve tolerance to ferroptosis. Further studies may provide potential therapeutic strategies targeting CSLC in HCC.
引用
收藏
页码:3703 / 3719
页数:17
相关论文
共 50 条
  • [21] The property of ovarian cancer stem-like cells and the prospect for immunotherapy targeted cancer stem-like cells
    Kuroda, Takafumi
    Hirohashi, Yoshihiko
    Torigoe, Toshihiko
    Mariya, Tasuku
    Asano, Takuya
    Tabuchi, Yudai
    Mizuuchi, Masahito
    Iwasaki, Masahiro
    Sato, Noriyuki
    Saito, Tsuyoshi
    ANNALS OF ONCOLOGY, 2015, 26 : 27 - 27
  • [22] HDAC inhibitor confers radiosensitivity to prostate stem-like cells
    Frame, F. M.
    Pellacani, D.
    Collins, A. T.
    Simms, M. S.
    Mann, V. M.
    Jones, G. D. D.
    Meuth, M.
    Bristow, R. G.
    Maitland, N. J.
    BRITISH JOURNAL OF CANCER, 2013, 109 (12) : 3023 - 3033
  • [23] HDAC inhibitor confers radiosensitivity to prostate stem-like cells
    F M Frame
    D Pellacani
    A T Collins
    M S Simms
    V M Mann
    GDD Jones
    M Meuth
    R G Bristow
    N J Maitland
    British Journal of Cancer, 2013, 109 : 3023 - 3033
  • [24] A mitochondorial enzyme MTHFD1L confers growth and cancer stem-like poperties in breast cancer cells
    Chen, Xiaoxi
    Nishimura, Tatsunori
    Gotoh, Noriko
    CANCER SCIENCE, 2018, 109 : 871 - 871
  • [25] Dysadherin can enhance tumorigenesis by conferring properties of stem-like cells to hepatocellular carcinoma cells
    Park, Jeong-Ran
    Kim, Ran-Ju
    Lee, Yoo-Kyung
    Kim, Soo-Rim
    Roh, Kyung-Jin
    Oh, Seung Hyun
    Kong, Gu
    Kang, Kyung-Sun
    Nam, Jeong-Seok
    JOURNAL OF HEPATOLOGY, 2011, 54 (01) : 122 - 131
  • [26] Cancer stem-like cells contribute to cisplatin resistance and progression in bladder cancer
    Zhang, Yi
    Wang, Zhi
    Yu, Jin
    Shi, Jia Zhong
    Wang, Chun
    Fu, Wei Hua
    Chen, Zhi Wen
    Yang, Jin
    CANCER LETTERS, 2012, 322 (01) : 70 - 77
  • [27] Role of prostate cancer stem-like cells in the development of antiandrogen resistance
    Kushwaha, Prem Prakash
    Verma, Shiv
    Kumar, Shashank
    Gupta, Sanjay
    CANCER DRUG RESISTANCE, 2022, 5 (02) : 459 - 471
  • [28] Brain cancer stem-like cells
    Kondo, Toru
    EUROPEAN JOURNAL OF CANCER, 2006, 42 (09) : 1237 - 1242
  • [29] HETEROGENEITY IN PRIMARY HUMAN HEPATOCELLULAR CARCINOMA IS DUE TO DIFFERENT SUBSETS OF CANCER STEM-LIKE CELLS WITHIN THE TUMOUR
    Baldan, F.
    Mazzucchelli, S.
    Colombo, F.
    Martin-Padura, I.
    Cattaneo, A.
    Rossi, G.
    Mazzaferro, V.
    Foglieni, B.
    Bertolini, F.
    Prati, D.
    Porretti, L.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S346 - S347
  • [30] A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells
    Shiyang Shen
    Xiao Xu
    Shiqi Lin
    Ying Zhang
    Huayu Liu
    Can Zhang
    Ran Mo
    Nature Nanotechnology, 2021, 16 : 104 - 113